Ultra-thinly traded WuXi Biologics (OTCPK:WXXWY +3%) is up, albeit on a scant 1,479 shares, on the heels of its announcement that WuXi Vaccines, its joint venture with Shanghai Hile Bio-technology, has inked a 20-year vaccine manufacturing agreement with an unnamed global vaccine leader valued at ~$3B.
Under the terms of the deal, WuXi Vaccines will build a dedicated production facility that, it says, should be on line in 2022.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.